Natixis Advisors, L.P. Adma Biologics, Inc. Transaction History
Natixis Advisors, L.P.
- $63 Billion
- Q2 2025
A detailed history of Natixis Advisors, L.P. transactions in Adma Biologics, Inc. stock. As of the latest transaction made, Natixis Advisors, L.P. holds 358,217 shares of ADMA stock, worth $5.01 Million. This represents 0.01% of its overall portfolio holdings.
Number of Shares
358,217
Previous 36,723
875.46%
Holding current value
$5.01 Million
Previous $729,000
794.79%
% of portfolio
0.01%
Previous 0.0%
Shares
4 transactions
Others Institutions Holding ADMA
# of Institutions
400Shares Held
197MCall Options Held
2.08MPut Options Held
1.56M-
Vanguard Group Inc Valley Forge, PA21.4MShares$299 Million0.01% of portfolio
-
Black Rock Inc. New York, NY18.6MShares$261 Million0.0% of portfolio
-
Invesco Ltd. Atlanta, GA12.8MShares$179 Million0.04% of portfolio
-
State Street Corp Boston, MA12.1MShares$169 Million0.01% of portfolio
-
Geode Capital Management, LLC Boston, MA5.91MShares$82.7 Million0.01% of portfolio
About ADMA BIOLOGICS, INC.
- Ticker ADMA
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 196,356,992
- Market Cap $2.75B
- Description
- ADMA Biologics, Inc., a biopharmaceutical company, engages in developing, manufacturing, and marketing specialty plasma-derived biologics for the treatment of immune deficiencies and infectious diseases in the United States and internationally. It offers BIVIGAM, an intravenous immune globulin (IVIG) product indicated for the treatment of primar...